Get started
Author

Andiliy G. Lai

Observed names: Andiliy G Lai, Andiliy Lai
OpenAlex ID: A5065142951
A small molecule–kinase interaction map for clinical kinase inhibitors
2005 · Miles A Fabian, William H Biggs, et al. · Nature Biotechnology · 1,934
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
2015 · Andiliy Lai, Mehmet Kahraman, et al. · Journal of Medicinal Chemistry · 261
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
2009 · Qi Chao, Kelly G. Sprankle, et al. · Journal of Medicinal Chemistry · 212
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 126
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · ACS Medicinal Chemistry Letters · 81
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)
2017 · Martin W. Rowbottom, Gretchen Bain, et al. · Journal of Medicinal Chemistry · 71
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis
2016 · Gretchen Bain, Kristen E. Shannon, et al. · Journal of Pharmacology and Experimental Therapeutics · 65
Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E
2011 · Martin W. Rowbottom, Raffaella Faraoni, et al. · Journal of Medicinal Chemistry · 60
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft
2015 · Steven P. Govek, Johnny Y. Nagasawa, et al. · Bioorganic & Medicinal Chemistry Letters · 50
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer
2018 · Johnny Nagasawa, Steven Govek, et al. · Journal of Medicinal Chemistry · 44
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors
2009 · Hitesh K. Patel, Robert M. Grotzfeld, et al. · Bioorganic & Medicinal Chemistry Letters · 31
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors
2011 · Mark W. Holladay, Brian T. Campbell, et al. · Bioorganic & Medicinal Chemistry Letters · 13
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft
2018 · Steven P. Govek, Celine Bonnefous, et al. · Bioorganic & Medicinal Chemistry Letters · 10
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2019 · James D Joseph, Beatrice Darimont, et al. · eLife · 7
Author response: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
2016 · James D Joseph, Beatrice Darimont, et al. · eLife · 5
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
2018 · Mehmet Kahraman, Steven P. Govek, et al. · Cancer Research · 3
Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2014 · James D. Joseph, Beatrice Darimont, et al. · Cancer Research · 1
Abstract A37: A novel class of selective estrogen receptor degraders display activity in pre-clinical models of ERα+ ovarian cancer
2013 · James D. Joseph, Beatrice Darimont, et al. · Clinical Cancer Research
Abstract A7: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer
2012 · Beatrice Darimont, Steven Govek, et al. · Clinical Cancer Research
Abstract A4: A novel class of selective ERα degraders acts as full antagonists/ inverse agonists and displays efficacy in pre-clinical models of endocrine-resistant breast cancer and endometrial cancer
2012 · Beatrice Darimont, Ninh Lu, et al. · Clinical Cancer Research
Abstract A133: A novel class of selective estrogen receptor degraders regresses tumors in preclinical models of endocrine-resistant breast cancer.
2011 · Beatrice Darimont, Steven Govek, et al. · Molecular Cancer Therapeutics
Identification and characterization of highly potent and specific FLT3 kinase inhibitors effective against FLT3-driven leukemia in culture and in vivo
2005 · Todd A. Carter, Daniel K. Trieber, et al. · Cancer Research
Works count: 22
Citation count: 2,974
H-index: 12
I10-index: 13
Year
Topic
Type